BOCA RATON, Fla., Feb. 10 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that Thomas H. McLain,
chairman, chief executive officer and president, and Henrik Rasmussen, M.D.,
Ph.D., senior vice president, clinical, medical and regulatory affairs, will
be presenting at the BIO CEO and Investor Conference 2006 on Tuesday, February
14, 2006, at 10:30 am ET at the Waldorf Astoria Hotel, Louis XVI Center/West,
301 Park Avenue, New York, New York. Mr. McLain will present a company
overview, and Dr. Rasmussen will speak about NicVAX(TM) (Nicotine Conjugate
Vaccine), the company's pipeline product for nicotine cessation.
The presentation will be webcast live at:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NABI&item_id=1165953
The webcast will be available through March 14, 2006.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. The company has three products on the market today: PhosLo(R)
(calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and
Aloprim(TM) [Allopurinol sodium (for injection)]. Nabi Biopharmaceuticals is
focused on developing products which address unmet medical needs and offer
commercial opportunities in our core business areas: Gram-positive bacterial
infections, hepatitis, kidney disease (nephrology) and nicotine addiction.
Click here for a complete list of our pipeline products. The company traces
its history to 1967 and is headquartered in Boca Raton, Florida. For
additional information about Nabi Biopharmaceuticals, please visit our
website: http://www.nabi.com .
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
Audio:http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NABI&item_id=1165953
CONTACT:
Tom Rathjen, Vice President, Investor
Relations, Nabi Biopharmaceuticals, +1-561-989-5800
|
